Bio Path Stock Price - BPTH

0.10 (1.75%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Bio Path Holdings Inc BPTH NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.22 4.0% 5.72 5.35 5.8467 5.51 5.50 00:00:06
Bid Price Ask Price Spread Spread % News
5.28 6.25 0.97 15.52% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
383 43,703 $ 5.61 $ 245,329 132,757 2.9203 - 17.5259
Last Trade Time Type Quantity Stock Price Currency
16:25:26 19 $ 5.82 USD

Bio Path Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 21.12M 3.69M - $ - $ - -3.27 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 4.00 -

more financials information »

Bio Path News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BPTH Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week6.046.405.255.73109,518-0.32-5.3%
1 Month5.206.974.34855.56127,2790.5210.0%
3 Months6.456.972.92035.11119,222-0.73-11.32%
6 Months6.989.452.92036.25117,957-1.26-18.05%
1 Year14.5517.52592.92039.58124,523-8.83-60.69%
3 Years80.00117.081.6029.09612,059-74.28-92.85%
5 Years270.00638.001.6066.08423,517-264.28-97.88%

Bio Path Description

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.

Your Recent History
Bio Path
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.